Kerrisdale Capital has taken a short position on Everspin Technologies, arguing the recent surge in its stock price is driven by misplaced enthusiasm around AI-related memory demand. Everspin's MRAM technology targets niche industrial markets rather than the high-speed AI server market, and its revenue has stagnated around $50-$65 million for years. Kerrisdale claims the stock's valuation is disconnected from its growth, trading at high multiples more fitting for leading AI memory firms. They estimate a fair value of $14 per share, implying a potential 60% drop from current prices.
TheBestReputation launched AIOverview.com, a free tool that scans five major AI search engines—ChatGPT, Claude, Google AI Overview, Gemini, and Perplexity—to show businesses how their brand appears in AI-generated search results. This is crucial as o...
Vuzix Corporation is exhibiting its advanced AI-powered smart glasses and waveguide solutions at SOF Week 2026 in Tampa, Florida. These products are designed for defense use, offering mission-ready optical performance in challenging environments, inc...
MoneyFlare has introduced an AI-powered trading bot designed to automate trading in both cryptocurrency and stock markets. This tool aims to simplify automated trading by handling market monitoring, data analysis, strategy execution, and trade manage...
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
ImmunityBio presented data showing its ANKTIVA plus BCG treatment outperformed two FDA-approved bladder cancer therapies, Adstiladrin and INLEXZO. The ANKTIVA combo achieved a 69.7% complete response rate versus 53.4% for Adstiladrin, with a longer m...
